ECVT & ECCT

09/10/2026

We were honored to welcome distinguished thought leaders Dr. B. Komane and Ms. T. Kaye from of South Africa at our office. This visit represents a powerful synergy, allowing our partners to experience the innovative ecosystem of ECCT, ECVT and ECBS firsthand.

We engaged in high-level, forward-thinking discussions with the C-Tech Group Indonesia team to align our visions and cultivate a robust collaborative framework. This interaction is a testament to our commitment to fostering global connections and driving impactful technological adoption. We are excited about the potential to co-create value and unlock new opportunities together in this new chapter of our mission at global stage.

10/06/2026

Riset menunjukkan bahwa terapi medan listrik yang dikombinasikan dengan kemoterapi memberikan hasil yang sangat baik pada kasus kanker tertentu. Dalam dunia medis, terapi medan listrik ini dikenal secara formal sebagai Tumor Treating Fields (TTFields) atau di Indonesia dikembangkan melalui metode Electro- Capacitive Cancer Therapy (ECCT). Berikut penjelasan AI.

11/04/2026

ECCT merubah lanskap terapi kanker paru-paru stadium lanjut, meningkatkan harapan hidup secara berlipat dibanding dengan terapi tanpa ECCT. Hal ini berdasarkan hasil studi Dr. Shinichiro Akiyama dari Jeoang yang dipresentasikan dalam konferensi dunia GLOBEHEAL 2026 ke-9 yang diadakan pada tanggal 12-13 Februari 2026 di Bali.

Dr. Akiyama, profesor tamu bidang onkologi klinis pada McGill University Medical School, Canada melakukan penelitian klinis bersama tim C-Tech Labs Edwar Technology di Tangerang terkait penanganan kanker paru-paru dengan ECCT sebagai terapi utama maupun tambahan untuk kasus kanker paru-paru stadium 3 dan 4.

ECCT meningkatkan harapan hidup penderita kanker paru-paru stadium lanjut 600-800% berdampingan dengan terapi standar dibanding apabila hanya menggunakan terapi standar saja. Hal ini berdasarkan hasil studi yang dipresentasikan dalam konferensi dunia GLOBEHEAL 2026 ke-9 yang diadakan pada tanggal 12...

02/03/2026

Group B breast cancers typically react well to ECCT treatment, causing tumors up to 3-5 cm in size to go away completely and revert to normal tissue. The way that various tumor types react to electric field treatment with ECCT depends on how those cancers are classified based on their electrical index. Tools for measuring the electrical activity index, which characterizes the subtypes, are provided by ECVT.

Different varieties of breast tumors react differently to the treatment. such as shrinkage (Groups C1 and C2), solid-turn-to-cystic (Group A), and solid-turn-to-necrotic (Group D). Together with a team from CTech Labs of Indonesia, Akiyama from the Clinical Oncology Department at McGill University in Canada published the study in the Journal of the World Academy of Anti-Aging and Regenerative Medicine 2024; 6: 20–33.

Link:https://waarm.or.jp/wp-content/uploads/2025/02/20-33_ECCT-Physical-Therapy-for-Cancer_Shinichiro-Akiyama.pdf

16/01/2026

CASE: Male, 44 years old, diagnosed with diffuse neuroendocrine carcinoma at the right neck, post-chemotherapy, followed with ECCT+chemotherapy.

After completing the first six cycles of chemotherapy, the cancer continued to grow. A CT scan revealed a mass measuring nearly 10 cm, pressing on a large blood vessel in her right neck, which had already been infiltrated.

The biopsy results indicated a diffuse neuroendocrine/non-Hodgkin's lymphoma, which had infiltrated the striated muscle tissue, the main muscles responsible for head and neck movement and swallowing and speaking.

Killing cancer cells with ECCT is relatively straightforward; cells die relatively quickly, especially for high-grade cancers. However, excessive cell death in the body can overload the body due to a flood of cytokines, the body's immune response to combat the dead cells. The patient was suggested to use ECCT combined with follow-up chemotherapy.

After using the device for two months, followed by one time of second chemotherapy cycles, while still using the device, the lump shrank significantly. He completed all six chemotherapy cycles while continuing to use the device. A PET CT scan after six months showed the lump in her neck had shrunk from 10 cm to 2-3 cm.

After completing six cycles, she continued using ECCT alone to completely remove the remaining lump. After two years of use, the lump was no longer palpable. He has continued using the ECCT device for general health maintenance for five years now. His condition is relatively normal and active.

08/01/2026

Ikuti pemaparan terkait sejarah awal pengembangan teknologi ECVT yang pertama dipakai oleh NASA dan Departemen Energi Amerika Serikat hingga pengembangan terbaru teknologi turunannya yaitu alat terapi kanker ECCT di podcast Bicara Iptek oleh inventornya langsung Dr. Warsito Purwo Taruno.

Link di komen.

Membahas mengenai teknologi tomografi dengan pengembangannya dalam terapi kanker di Indonesia.Kontak tim Dr. Warsito untuk terapi Kanker bisa melalui:https:/...

03/01/2026

Lung cancer remains a leading cause of cancer-related mortality worldwide. Electro-Capacitive Cancer Therapy (ECCT), a non-invasive treatment utilizing alternating electric fields, has emerged as a promising adjunctive modality by selectively disrupting cancer cell mitosis. This study presents a case series evaluating the clinical outcomes of ECCT as an additive therapy for patients with advanced lung adenocarcinoma.

Results shows that five patients observed in this study achieved a partial response (PR), and one maintained stable disease (SD), with significant tumor regression observed across all cases. The treatment was exceptionally well-tolerated, with no severe adverse events reported. Clinical improvements were observed irrespective of the patients' EGFR mutation status.

This case series suggests that ECCT is a safe and effective adjunctive therapy for stage IV lung adenocarcinoma, significantly enhancing the efficacy of standard treatments across different molecular subtypes. These promising real-world results align with emerging evidence from larger trials and preclinical studies on electric field-based therapies. These findings warrant further investigation in larger, prospective clinical trials to establish ECCT's definitive role in precision oncology frameworks.

DOI URL:
https://dx.doi.org/10.47746/FMCR.2025.6505

基本的に正常細胞に作用しないため、副作用は抗がん剤に比べて非常に少なく、重篤な副作用は報告されていません。

03/01/2026

CASE: A 40-year-old woman was diagnosed with a bone tumor in her right thigh. It recurred two months after surgery and radiation.

A PET-CT scan two months after surgery showed recurrence in the post-surgery and radiation area, along with metastasis to the lungs and lymph nodes surrounding the trachea, bronchi, and supraclavicular and neck lymphnodes. A biopsy revealed a poorly differentiated adenocarcinoma with ALK-positive mutation detected. The mass in her right thigh likely originated from her lung.

This case is considered end-stage. Poorly differentiated adenocarcinoma is a highly aggressive type that generally has a poorer prognosis than moderately or well-differentiated types. In general, the prognosis for end-stage lung cancer is relatively poor, with survival rate only around 6-12 months even with treatment.

However, this type has a better response to ECCT than less aggressive types. Poorly differentiated adenocarcinomas have higher electrical polarity than moderately or well-differentiated types, resulting in a better response to ECCT. Cells die more quickly with exposure of the electric field, dead cells are discharged more easily due to their softer nature. Probability to achieve remission is higher regardless of staging. Metastasis is relatively less issue with ECCT as long as the spread remains in the form of small nodules, so the level of damage to the invaded tissue is not too severe.

In this case, the patient also received targeted drugs in combination with the usage of ECCT device. ECCT effectively kills malignant cells, while the targeted drugs suppress the growth factor of the cells. If both work well, remission is highly possible, even in cases with extensive spread.

The success rate of this combination therapy is still influenced by how quickly the dead cells are discharged to outside of the body through the body's natural mechanisms as well as the extent of tissue/organ damage that has been invaded by malignant cells. For cases with widespread metastasis in the form of small nodules, this is generally the case.

A CT scan after 3 months of use of the device showed the main mass in the lung had shrunk from 3.8x2.3 cm to 1.8x1.3 cm. Another PET-CT scan after 6 months of usage of the device showed the malignant mass had been relatively cleared. The patient's general condition is relatively normal.